PHARM2FARM
11.3.2021 10:32:12 CET | Business Wire | Press release
A new anti-viral mask which kills 99.9% of Covid-19 virus within five minutes of contact has been launched today – offering an unparalleled level of protection against viruses not just for those around them but for the wearer too.
Aimed at all types of industry, from hospital and care homes, to schools, to the retail & leisure industries, Pro-Larva differs from conventional masks because, as well as protecting those around the wearer, it protects the wearer themselves, using revolutionary copper nanoparticle technology developed here in the UK.
Antony Legge, Chairman of the parent company Pharm2Farm explains: “Conventional surgical-type TR2 masks only block virus from exiting the mask – they don’t have an active mechanism for killing it once it’s trapped in the mask. Pro-Larva has been designed to use existing barrier technology but also to combine it with α-virion™, a copper nanoparticle technology that kills 99.9% of the virus once it is trapped in the mask.”
This viricidal layer is effective for up to seven hours. Current surgical masks are only effective for around two hours, which requires health care professionals in Intensive Care Units (ICUs) to wear between 4-10 masks per day.
Because of Pro-Larva’s longer effective life this greatly reduces the number of masks required, therefore reducing costs for the hospital or care home. Pro-Larva is also self-sterilising – killing Covid-19 on contact means there is no infection risk from discarded masks after use, removing any potential biohazard.
The effectiveness of the mask against the coronavirus and Influenza has been tested by an independent laboratory and a leading UK university. It has also received European regulatory approval and carries a CE mark, meaning it has been independently reviewed.
The Pro-Larva idea was developed by scientists at Pharm2Farm led by Dr Gareth Cave. Pharm2Farm recently installed a face mask production line in Nottingham, UK and are working with European and global face mask manufacturers to scale-up the supply of Pro-Larva to meet demand.
Dr Gareth Cave, founder of the technology and Pharm2Farm, added: “Helping healthcare professionals protect themselves, their co-workers and patients is very important, and we are keen to support the NHS. However, there are many other categories of frontline workers we are looking to engage with – from schools to care home workers, to the retail and leisure industries – who could benefit from this next generation mask.”
-Ends-
Notes to Editors
About Pharm2Farm
Pharm2Farm is a VC backed Nottingham Trent University spin-out which provides advanced nanoparticle-based solutions for plant, animal and human care through a patented novel production process. For more information, please visit the website: www.pharm2farm.org
About the Pro-Larva mask
The 4 ply anti-viral disposable medical mask from Pharm2Farm Ltd is proven to kill up to 99.9% of coronaviruses and 90% of influenza for up to 7 hours. The mask is splash resistant with a melt blown filter and hypoallergenic layers and uses Pharm2Farm’s proprietary α-virion™ virucidal technology, featuring copper nanoparticles. The Pro-Larva mask is CE marked and its α-virion™ layer has been certified to ISO 18184 standards. ISO 18184 is a standard protocol to quantify the antiviral properties of textile materials. For more information about Pro-Larva mask, its features and suppliers, please visit: https://pro-larva.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Advanced Edge AI Solutions at the FPGA-forum 202628.1.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA-forum 2026 taking place February 11 – 12, 2026 in Trondheim, Norway. As part of the event, Lattice Corporate Vice President of Software Solutions and Applications Engineering Eleena Ong will deliver a keynote presentation exploring how rapidly maturing AI technologies can turn FPGA platforms into innovation canvases for a much broader range of developers, sparking new application possibilities. Lattice will also deliver a technical presentation and host a demo showcase focused on how its low power FPGA solutions are advancing connectivity and edge AI applications. Who: Lattice Semiconductor What / When (GMT+1): Lattice Demo Showcase (Table #3), Feb 11-12 Keynote Feb. 11, 9:30 a.m. “Unlocking the Next Wave of FPGA Innovators with Generative and Agentic AI” Technical Presentation Feb. 12, 10 a.m. “Smaller. Cooler. Smarter: Lattice FPGAs’ Path to Uncompromised
Egon Zehnder Elects German Herrera as New Chair28.1.2026 20:01:00 CET | Press release
Herrera succeeds Michael Ensser, who will remain an active member of the Firm after his term in a planned transition. Egon Zehnder, the world’s premier leadership advisory firm, today announced that, in accordance with its established governance and three-year election cycle, German Herrera has been elected as the Firm’s next Chair by its worldwide partnership. Herrera will assume the role effective March 1, 2026. He will succeed Michael Ensser, who has held the position since 2022, in a planned succession at the conclusion of his regular term. Herrera joined the Firm in 1998 in Bogotá and has helped shape the Firm’s global presence, taking on a broad range of leadership roles, from co-leading the Global Family Business Advisory Practice to serving on the Executive Committee and the Market Council. Most recently, Herrera has guided Egon Zehnder’s U.S. market through a period of impressive growth and transformation, which today includes 15 offices and more than 150 consultants. As the f
De' Longhi Group - Record Preliminary 2025 Revenues of €3.8 Billion, up 10.4% at Constant Exchange Rates28.1.2026 19:25:00 CET | Press release
The Group closed 2025 with brilliant results and solid growth at constant currency across both divisions throughout the year, further confirmed by an organic expansion of 8.2% in Q4 Below are the preliminary 2025 revenues for the De’ Longhi S.p.A. Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128191504/en/12 months, revenues at € 3,801.5 million, growing at 8.7% (+10.4% at constant currency); fourth quarter, revenues at € 1,340.0 million, growing at 5.7% (+8.2% at constant currency). Fabio de' Longhi, CEO of the Group, stated: "The Group achieved solid growth at constant currency of 10.4% in 2025, characterized by consistent results throughout the year. We are particularly pleased with the excellent performance achieved in the fourth quarter, which successfully overcame the challenges posed by the current market environment. The household division consolidated its recent growth momentum during the quarter, with or
Organon Completes Divestiture of JADA® System to Laborie28.1.2026 18:45:00 CET | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms. Indications for Use The JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Contraindications Ongoing intrauterine pregnancy Untreated uterine rupture Unresolved uterine inversion Current cervical cancer Known uterine anomaly Current purulent infection of vagina, cervix, or uterus For C-sections: Cervix <3 cm dilated before use of JADA Warnings Avoid excessive force when inserting JADA into the uterus or trauma to uterine wall may occur, including perforation. The safety and effectiveness of the JADA System in delivery at a gestational age <34 weeks or, if multiples, uter
Laserfiche Expands AI Data Capture with Auto-Classification to Transform Data into Business Intelligence28.1.2026 16:00:00 CET | Press release
New intelligent features automatically organize and classify documents, transforming how organizations manage information at scale. Laserfiche — the leading SaaS provider of intelligent content management — today announced major enhancements to its AI-powered data extraction tool, Smart Fields. The update introduces automated document classification and tagging, allowing organizations to move from unstructured content to informed decisions in seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128228490/en/ Using natural language prompts instead of rigid, ruled-based OCR, Smart Fields can now identify document type — such as invoices, taxpayer identification forms, or student transcripts — and automatically apply the correct metadata template using AI. Users can also use Smart Fields to automatically add informational and security tags to files that meet certain criteria, defined using a natural language prompt. Users
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom